Appian (Nasdaq: APPN) and PSI CRO announced the launch of their first joint AI-powered process orchestration solution. The new offering automates clin...
CellsBin®, a biotechnology company pioneering Rare-Cell Biology™, announced that it has received a Direct-to-Phase II Small Business Innov...
American Hospital Dubai ("AHD"), one of the Middle East's premier private healthcare providers and a member of the Mayo Clinic Care Network, and HEI Global...
Late-breaking results to be presented in an oral presentation at ESMO 2026 PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER...
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42%...
HighTide Therapeutics, Inc. (02511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapie...
BioAgilytix, a global bioanalytical Contract Research Organization (CRO), announces the expansion of its Australian laboratories through the op...
Approval is based on Phase 3 results demonstrating significant progression-free and overall survival benefits, with teclistamab reducing risk of disease ...
What began with a single cardiac catheterization laboratory four decades ago has evolved into an advanced cardiovascular program at King Faisal Specialist ...
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted...
82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer t...
Objective responses observed across eight distinct tumor types, including breast, colorectal, endometrial, gastroesophageal junction,...
Advanced Clinical, a global clinical research organization (CRO) providing full-service clinical development, functional service provider (FSP) solutions a...
Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable...
© 2026 Biopharma Boardroom. All Rights Reserved.
